Last reviewed · How we verify
Control group(autologous ICBG)
Autologous iliac crest bone graft (ICBG) provides structural support and biological factors to promote bone healing and regeneration at the graft site.
Autologous iliac crest bone graft (ICBG) provides structural support and biological factors to promote bone healing and regeneration at the graft site. Used for Bone defects and non-unions requiring surgical reconstruction, Spinal fusion procedures, Maxillofacial and craniofacial bone reconstruction.
At a glance
| Generic name | Control group(autologous ICBG) |
|---|---|
| Sponsor | The University of Texas Health Science Center, Houston |
| Modality | Small molecule |
| Therapeutic area | Orthopedic Surgery / Bone Regeneration |
| Phase | FDA-approved |
Mechanism of action
ICBG is a surgical procedure in which bone tissue is harvested from the patient's own iliac crest and transplanted to another site requiring bone repair or reconstruction. The graft provides osteoconductive scaffolding, osteoinductive growth factors (including BMPs and other cytokines), and osteogenic cells that facilitate new bone formation and integration with host bone.
Approved indications
- Bone defects and non-unions requiring surgical reconstruction
- Spinal fusion procedures
- Maxillofacial and craniofacial bone reconstruction
Common side effects
- Pain at donor site (iliac crest)
- Infection
- Hematoma
- Nerve injury
- Graft site complications
Key clinical trials
- Cost Effectiveness in Alveolar Bone Grafting in Patients With Cleft Lip and Palate (PHASE4)
- KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: